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Abstract 
To compare the clinical effectiveness of total (TS) or partial (PS) splenectomy in pediatric 
hereditary spherocytosis, a systematic review and meta-analysis was performed (PROSPERO 
registration CRD42015030056). There were 14 observational studies comparing pre- and post-
operative hematologic parameters. Secondary outcomes include in-hospital infections, surgical 
complications, symptomatic recurrence and biliary disease. TS is more effective than PS to 
increase hemoglobin (3.6 g/dL vs 2.2 g/dL) and reduce reticulocytes (12.5% vs 6.5%) after one 
year; outcomes following PS are stable for at least 6 years. There were no cases of overwhelming 
post-splenectomy sepsis. A population-based patient registry is needed for long-term follow-up. 
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Introduction 
Hereditary spherocytosis (HS) is a rare genetic disease affecting the erythrocyte cell 
membrane, producing characteristically spherical erythrocytes (spherocytes). The worldwide 
prevalence of HS is approximately 1 in 2,000 people [1–3]. The main molecular defects in HS 
arise from a heterogeneous set of mutations to cytoskeletal proteins facilitating linkage to the lipid 
bilayer [4], Weakening the mechanical integrity of the cell membrane. Signs and symptoms of HS 
may include splenomegaly, severe anemia, jaundice, reticulocytosis, fatigue, abdominal 
discomfort [5]. These symptoms are widely recognized to be caused by hemolysis of immature 
reticulocytes undergoing conditioning in the spleen. 
The degree of splenomegaly is a generally reliable indicator of the severity of hemolysis, 
anemia and risk of developing gall stones. An enlarged spleen is also vulnerable to traumatic 
rupture. If the degree of anemia is too great, surgical management of HS by splenectomy remains 
the only intervention. Management of HS by splenectomy has historically been focused on total 
splenectomy (TS) which was performed through a laparotomy incision. In the early 1990s, the 
laparoscopic approach was successfully adopted for splenectomy in HS patients [6], and became 
a more popular choice of technique. The spleen is a major lymphoid organ in the body and the risk 
of infection caused by staphylococci and Gram-negative enteric organisms is high in the early 
post-operative period. Following TS, there is increased susceptibility for many years to potentially 
fatal overwhelming post-splenectomy sepsis (OPSS; otherwise called overwhelming post-
splenectomy infection) from these encapsulated bacteria such as pneumococci, Neisseria 
meningitides, Haemophilus influenzae and staphylococci [7]. The risk of OPSS from these 
organisms has been reduced as most centres across North America and Europe use prophylactic 
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vaccinations and prophylactic antibiotics prior to elective splenectomy, and if possible, delay the 
surgery until the patient over five years old [4]. It is suggested that PS confers some residual 
immune competence against encapsulated organisms. The level of circulating IgM memory B cells 
after splenectomy and the percentage of pitted erythrocytes have been used as surrogate markers 
for immune competence against encapsulated organisms or residual splenic function [8, 9]. 
However, these observations need further validation through prospective, controlled studies. This 
review aims to determine how PS and TS compare when performed for pediatric HS. 
Methods 
Systematic Review Protocol 
Methods of the present systematic review and meta-analysis were pre-specified and 
documented in a protocol (PROSPERO registration CRD42015030056). The study question was 
translated into a PICO-formatted grid and was developed to guide the selection of appropriate 
search terms (Table I), in accordance with the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines [10] (Supplemental Table SI). 
The population of interest (P) were children, 18 years of age or younger, diagnosed with 
HS. The intervention (I) was a PS as compared (C) to TS, performed to correct anemia, the primary 
indicator of HS severity. While PS can be performed as one of two surgical procedures, a less 
aggressive PS and a more aggressive near-total splenectomy, both are treated as PS for this review. 
The former leaves between a splenic remnant of about 15-30% in size; the latter leaves a splenic 
remnant supplied by a single pedicle, of about 10-15% [11]. This choice is left to the experience 
of surgeon. The specific surgical technique was not considered here. Primary outcomes (O), 
chosen based on a pilot search, were pre- and post-operative hemoglobin concentration (g/dL) and 
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percent reticulocytes because these are the most commonly reported outcomes, and often only with 
one year of follow-up; these were of primary interest because they are a marker of anemia and 
erythropoiesis, respectively. Secondary outcomes included in-hospital infections, surgical 
complications, biliary disease, OPSS, recurrence of symptoms and splenosis. All study designs (S) 
were included for initial screening except case-series with less than five cases. 
Search Strategy 
A systematic literature search protocol was conducted with the help of a research librarian 
using the PubMed, EMBASE, Web of Science and CINAHL databases up to Oct. 1, 2015 for 
studies published with English full-text. Search terms regarding the population of interest, 
intervention and indication, and comparator and outcome were used to identify eligible studies 
(Table I). The reference lists of relevant articles were then manually searched for additional 
studies. 
Grey literature are publications produced by individuals or organizations, considered to be 
outside of the traditional commercial or academic publishing and distribution channels; sources 
searched using “spherocytosis” or “splenectomy” include: clinical trial databases (UK Clinical 
Trials Gateway; ClinicalTrials.gov), systematic review registries (Cochrane Library; 
PROSPERO), thesis depositories (Library and Archives Canada; NTLTD, EThOS), health service 
agencies (WHO; US CDC, Health Canada; CADTH) and grey literature-specific databases 
(OpenGrey; Grey Literature Report). One clinical trial was identified (NCT01276561) but 
excluded for lack of relevance and have not yet published any results. Some authors were contacted 
by e-mail to provide further details, yet was supplied in only one case [12]. 
Study screening 
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All retrieved studies from database searches were included in the screening process to 
create a systematic, precise, and validated search strategy. Records were imported into EPPI-
Reviewer (version 4.5), duplicates removed, and remaining entries were screened on title and 
abstract for relevance, and full-text for full consideration. Additionally, eligible studies were 
included after reading relevant review articles and their reference lists. A complete list of inclusion 
and exclusion criteria is presented in Table II. Studies were not included if they failed to report 
on a relevant outcome. 
Articles were screened by two independent reviewers in three levels (title, abstract and full-
text) and differences were resolved by consensus. Level 1 (title) screening was based on relevance, 
level 2 (abstract) screening ruled in studies based on patient population and outcomes, and level 3 
(full-text) screening was carried out on studies that might satisfy all criteria of the PICOS. Level 
3 screening inter-rater agreement was 83% (kappa=0.64). Then each article was critically 
appraised and a risk of bias assessment was made using Downs and Black checklist [13], which 
was originally validated for appraising surgical interventions. Downs and Black score ranges were 
given corresponding quality levels as previously outlined: excellent (26–28); good (20–25); fair 
(15–19); and poor (≤14) [14]. Articles rated as poor were excluded for severe risk of bias. In total, 
14 studies met the sufficient quality criteria and were included in this meta-analysis (Table III) 
[12, 15–26]. 
Meta-analysis and publication bias 
Data were extracted into a spreadsheet for analysis. Hemoglobin and percent reticulocytes 
were compared using the pre- to post-op difference. When the standard deviation of an estimate 
was not reported, it was calculated where possible or estimated from individual patient data. A 
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fixed-effects model was used to explore the overall effect of surgery, where each study was 
weighted by the inverse variance method (Figure 1). To assess heterogeneity between studies, the 
chi-square test and I2 statistic were calculated; an I2 value greater than 75% suggested high 
heterogeneity among studies. Publication bias was assessed by inspecting the funnel plot and 
Egger's method. 
Results 
Study Characteristics 
From the initial search there were 23 studies included after full-text screening for quality 
review (Figure 1). In total, 14 observational studies were included after risk of bias assessment 
with a total of 2,224 patients, including one cross-sectional study (Table III) and no identified 
trials. The primary reason for exclusion of studies was incomplete data reporting or a high 
perceived risk of selection and reporting bias. The funnel plot of hemoglobin concentration 
suggested publication bias (Figure 3). However, it is difficult to determine whether this asymmetry 
represents a true publication bias, or if there is a true heterogeneity of intervention effects. It is 
more likely caused by the small number of studies having few observations. Within each outcome, 
the studies do not overlap in patient population based on reported methodology. 
Hemoglobin 
All studies reported qualitative resolution of anemia, often increasing hemoglobin to 
clinically normal values. One year following splenectomy, eight studies reported post-operative 
hemoglobin changes for TS and PS, then only four reports concerned PS followed for at least three 
to four years (Figure 2). PS significantly increased the hemoglobin concentration by an average 
of 2.20 g/dL (95% CI: 1.96 g/dL to 2.45 g/dL; P<0.001) and following TS resulted in an average 
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increase of 3.60 g/dL hemoglobin (95% CI: 3.08 g/dL to 4.12 g/dL; P<0.001) (Figure 2A). Three 
to four years following PS, there was an average increase of 3.22 g/dL (95% CI: 2.49 g/dL, 3.94 
g/dL; P<0.001) (Figure 2B), and after five to six years, there was a significant increase of 2.21 
g/dL (95% CI: 1.42 g/dL, 2.99 g/dL; p<0.001) (Figure 2C). A single report followed PS patients 
for a decade [15], finding a similar plateau effect. 
Reticulocytes 
Four studies reporting percent reticulocyte were included for meta-analysis [20–22, 26] 
(Figure 4). Absolute reticulocyte counts could not be used for lack of comparison among children 
of different ages. Following splenectomy, there is a significant decrease in percent reticulocytes, 
though values typically remained above the normal range (1.5%) in both TS and PS at all time 
points (Figure 4). Following PS, percent reticulocytes decreased from baseline by an average 
decrease of 6.5% (95% CI: -7.4% to -5.6%) after one year (Figure 4A), 12.5% (95% CI: -12.7% 
to -12.2%) after three to four years (Figure 4B), and 7.8% (95% CI: -10.7% to -4.9%) after five 
to six years (Figure 4C). Percent reticulocytes remain persistently decreased from baseline by 
about half to a final value around 4-6%. The profile for TS is more limited but also greater in 
magnitude after one year, decreasing by an average of 12.5% (95% CI: -12.7% to -12.2%) to about 
2-3% after one year (Figure 4A). This magnitude of effect of TS is heterogeneous, and could be a 
result of selection bias if those children undergoing TS had larger spleens or more severe 
hemolysis. It is expected that erythropoiesis correlates with the degree of hemolysis and therefore 
TS should have a greater effect than PS. The largest study of TS in this review does not include 
lab or clinical values [27]. 
Infections and Mortality 
8 
Fatal events were extremely rare across all reported studies. One 4-year old female died 
due to unrelated splenic necrosis 8 weeks following PS [11, 24], in a total of 2,119 reported patients 
across 13 studies, and no reported cases of OPSS. The study of 1,657 TS patients [27] used the 
Agency for Healthcare Research and Quality’s Pediatric Quality Indicators to profile the safety of 
the procedure. The found in-hospital pneumonia was extremely rare (<0.6%). A study of similar 
magnitude for PS has yet to be conducted. 
Presence of Accessory Spleens 
Four studies reported that 4.5% of HS patients have accessory spleen(s) (80/1,770) but the 
best estimate in this review is about 3.6% (59/1,657) [27]. This is likely to be underestimated due 
to a lack of reporting, but is on the low end of the estimated 4-27% reported for other conditions 
([28, 29] and references within). When present, surgeon preferences affect the decision to remove 
accessory spleens, where some choose to remove them routinely [26], whereas others do not [18], 
with no completion splenectomy after two years in these patients. 
Splenic remnant regrowth 
The volume of regrowth is highly heterogeneous, ranging from 0-170% of its initial size 
[20, 24], consistent with others [30]. Remnant regrowth is does not appear to be associated with 
recurring anemia [24, 30], however, regrowth is lowest at younger age and severe disease [24]. 
Splenomegaly, recurrence of symptoms and secondary splenectomy 
Splenomegaly was reported in 241 of 1,716 individuals (14.0%). Only with excessively 
large spleens (greater than 1,500 g), do laparoscopic techniques become cumbersome. Recurrence 
of symptoms (anemia, jaundice, fatigue or abdominal pain) was not common (5-10%), and in 
some, secondary splenectomy was indicated (5%) [15, 16, 20, 23, 24]. 
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In-hospital complications and adverse surgical events 
Paralytic ileus was the most common in-hospital complication (1.5%), followed by urinary 
and respiratory complications (1% each), acute pancreatitis and accidental puncture or laceration 
during surgery (<1% each)  [27]. One HS patient had a sequestration crisis following splenectomy 
[21]. 
Cholelithiasis and cholecystitis 
Biliary disease is among the most common associated problem with long-standing 
hemolysis. Among TS patients, cholecystectomy was the most common concurrent procedure 
(26.7%), of which, 40% suffered from cholelithiasis [27]. The role of prophylactic 
cholecystectomy performed during splenectomy in children suffering from HS was questioned in 
the late 1990s [31], who found that this was indicated when symptomatic gall stones were present. 
The degree of splenectomy does not seem to be associated with cholecystectomy and 
cholelithiasis. 
Patient health measures and quality of life 
 Following splenectomy, abdominal pain was improved [19, 20], sleep quality improved 
[32] and two studies noted growth spurts in children [15, 32]. Lastly, three studies reported that 
quality of life improved using a composite score of some or all of pain, chronic fatigue, or return 
to physical exercise [15, 16, 32]. These quality of life metrics were not described using standard 
assessment tools and are open to interpretation. Clinical experience would suggest splenectomy is 
favourably improves pain and quality of life, despite the residual risk of PS for recurrent anemia. 
Length of hospital stay and duration of surgery 
While duration of hospital stay and duration of surgery have been reported to be different 
10 
between TS and PS, these data suggests that they are comparable. The length of stay for TS is 
between 2-4 days [27]. However, more recent studies on TS find shorter stays of 1-4 days. 
Likewise, length of stay for PS was 2-4 days. Surgeries that are uncomplicated and performed 
without additional procedures are typically 50-75 minutes. Both length of stay and duration of 
surgery will be influenced by the surgeon's technical proficiency and experience. 
Discussion 
This meta-analysis finds that both total and PS adequately resolve short-term anemia in 
pediatric HS patients. There is a general theme that there is longer follow-up data available for PS 
patients, and the extent of detailed reporting varies. In the short-term post-operative period, 
splenectomy is generally safe and well tolerated, with extremely low risk of death and no reported 
cases of OPSS. This agrees with a meta-analysis which included adult hemolytic anemia patients 
[33]. 
Consensus guidelines for which data should be collected during routine monitoring of the 
HS patient are needed. For instance, hemoglobin concentration and reticulocytes are inexpensive 
and worthwhile to collect. For this reason and based on a pilot search of the literature, they were 
used in this review because of their relation to anemia and splenic function, and also that anemia 
is an independent risk factor of future cardiovascular disease [34]. The best way forward would be 
a discussion among experts with the patient and their family, in order to confirm what are important 
and clinically relevant outcomes for the managing clinician and the patient. Ideally, such 
information can be collected at regular clinic visits. 
Several quality of life instruments measuring of pain, health and functioning exist. A few 
examples are the Pediatric Quality of Life Inventory (PedsQL™), WHO International 
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Classification of Functioning or the Brief Pain Inventory. A standard inventory should be used 
during follow-up visits to better allow for comparison across institutions. Improvement in 
abdominal pain and return to physical activity were infrequently described, but can be quickly and 
easily determined using a standardized questionnaire. The goal of a related, on-going clinical trial 
is to examine the patients' perception of scar formation, suggesting that cosmesis is an important 
factor to some patients and their families. 
Measures of splenic function need also to be collected and validated prospectively. Pitted 
erythrocytes, measured by phase microscopy, are the gold standard of phagocytic function and is 
widely available. The normal clinical range is 0–4%, but may increase to 70% in clinically relevant 
splenomegaly. Data from sickle cell patients suggest a value of 15% or less is associated with 
immune competence and fewer instances of sepsis [35–37]. In contrast, Howell-Jolly bodies 
poorly correlate with other measurements [8]. Imaging modalities may be used for functional 
assessment. MRI can measure splenic volume in HS [23] and splenosis [29]. Scintigraphic scans 
using 99m-technetium labelled heat-damaged, autologous erythrocytes measure splenic function 
due to (mostly) splenic sequestration of the cell membranes, and splenic volume. However, 
scintigraphy is unlikely to be a cost-effect or common option in the pediatric population, and is 
only available in specialized centres. There is the possibility that sequestration-based measures in 
HS patients are at risk of increased false positives and could diminish its diagnostic utility [38]. 
Finally, ultrasonography can assess splenic size, portal hypertension, and gallstones, which may 
be an economical, safe, first-line imaging approach. 
The extent of splenectomy positively correlates with hematologic improvement. All studies 
agreed that TS adequately resolves anemia to normal or near-normal hemoglobin concentrations. 
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Hematologic values following PS remain stable for at least five years, and this should also be 
expected following TS. There is less erythropoiesis following splenectomy, though percent 
reticulocytes remain abnormally elevated due to residual hemolysis. It seems prudent to consider 
PS when modest improvements in hemoglobin and reticulocytes are required, and to consider TS 
in more severe instances.  
Following splenectomy, residual hemolysis increases the risk of gallstone formation, and 
symptomatic gall stones or cholecystitis, especially with severe disease or delayed splenectomy 
[20]. Secondary TS is indicated when symptoms recur following PS, and is more likely to be 
required in severe disease. The genotypic and phenotypic severity of HS should be characterized 
to help predict patient outcome, as disease severity is a cumulative effect of spectrin and band 3 
protein deficiency, or a relative imbalance in their abundance [39]. The level of methemoglobin 
bound to the erythrocyte membrane negatively affects the post-splenectomy hemoglobin 
concentration, another possible marker of outcome [39]. 
An often cited concern for avoiding TS is that the risk of OPSS was perceived to be greater 
than that of PS. An older review of 5,902 TS cases produced an estimated post-operative sepsis 
rate of 4.4% and a mortality rate of 2.2% [40]. One meta-analysis observed post-operative sepsis 
rates of 5-12% for TS and 0–11% for PS [33]. However, these mortality rates included both adult 
and pediatric patients across several hemolytic disorders. The reason for the significantly reduced 
mortality in pediatric HS over the past two decades is mostly influenced by prophylactic antibiotics 
and vaccinations, and to delay elective splenectomy until age five [4, 41]. This delay is even 
reflected in the patient demographics (Table III). Furthermore, no case of OPSS in a pediatric HS 
patient who has received prophylactic immunization and antibiotics were found. 
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Whether the splenic remnant retains immune competency is uncertain. The resident 
population of IgM memory B cells in the spleen constitute a major defense against encapsulated 
bacteria. However, splenectomy severely reduces this B cell population [9]. Several documented 
cases of OPSS or serious bacterial infection in patients with splenosis or accessory spleen tissue 
have been documented [29, 42–44], and some cases of fulminant pneumococcal infections occur 
more than 20 years after splenectomy [45]. There is no clear correlation that the volume of splenic 
regrowth or splenosis offers immune protection, and preliminary findings exacerbate this risk as 
immune protection declines with age independent of splenectomy [29, 46]. The immunogenic 
response to pneumococci and meningococci vaccination are also less than ideal following 
splenectomy performed for congenital hemolytic disorders [46–48]. This scanty data supports the 
extra concern noted in a recent review of vaccination guidelines for the care of hyposplenic 
individuals [49]. It remains unknown if splenectomized children experience more frequent 
bacterial infection in later adulthood. 
There are limitations to this review. First, there is a limited length of follow-up. Second, 
these reports mostly represent experiences of single institutions, and are often based on a small 
patient sample. While these patients experience moderate to severe disease, this review focused 
on reports which endeavoured to use systematic collection procedures, such as institutional 
reviews, so as to limit some forms of selection bias. While the recovery of hemoglobin, resolution 
of hemolysis, prevention of cholelithiasis and the consequent hepatobiliary disease and future risk 
of vascular disease in HS patients are all important issues for both the clinician and the patient, the 
choice of TS vs PS in achieving an optimal outcome is not yet clear. 
This review identifies key opportunities for improving pediatric patient care. First, 
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establishing a population-based disease registry for tracking outcomes of HS. Efforts in this 
direction have been started by the Splenectomy in Congenital Hemolytic Anemia [21]. Such a 
multi-institution collaboration, prospectively following patients, should be able to address 
questions of long-term questions of recurrent hemolysis, gall bladder and liver disease, as well as 
estimate burden of morbid bacterial infections. It appears feasible based on available data to 
conduct a clinical trial comparing PS to TS to examine these outcomes. Second, functional splenic 
assessments should be made regularly, possibly incorporating diagnostic imaging to monitor 
splenic function and splenic regrowth, gall stones and liver disease. Third, careful monitoring for 
history of bacterial infection and vaccination history should continue. Data on serious infection 
incidence, lab results and clinical imaging can be incorporated into such a patient registry. Finally, 
individualized intervention is advocated with continued surveillance; the optimal choice of 
treatment and outcomes should clinically relevant and but confirmed with the patient. 
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Figure Legends 
 
Figure 1. Flow diagram of study selection 
 
Figure 2. Meta-analysis of absolute post-operative difference in hemoglobin concentration (g/dL) 
from pre-operative baseline. Mean pre- and post-operative hemoglobin concentrations and the 
pooled standard deviation are listed. (A) After 6 months to 1 year follow-up, average hemoglobin 
concentration increased following PS by 2.20 g/dL (95% CI: 1.96 g/dL to 2.45 g/dL; heterogeneity 
I2 = 65.3%) and following TS by 3.60 g/dL (95% CI: 3.08 g/dL to 4.12 g/dL; heterogeneity: 
I2 = 0.0%). (B) After 3 to 4 years follow-up, average hemoglobin concentrations increased 
following PS by 3.22 g/dL (95% CI: 2.49 g/dL to 3.94 g/dL; heterogeneity I2=0.0%). (C) After 5 
to 6 years follow-up, average hemoglobin concentrations increased following PS by 2.21 g/dL 
(95% CI: 1.42 g/dL to 2.99 g/dL; heterogeneity I2=44.8%).  
 
Figure 3. Funnel plot of absolute mean difference of measured hemoglobin.  
 
Figure 4. Meta-analysis of post-operative difference in percent reticulocytes from pre-operative 
baseline. Mean pre- and post-operative percent reticulocytes concentrations and the pooled 
standard deviation are listed. (A) After 6 months to 1 year follow-up, average percent reticulocytes 
decreased following PS by 6.5% (95% CI: -7.4% to –5.6%; heterogeneity I2 = 0.0%) and following 
TS by 12.5% (95% CI: -12.7% to -12.2%; heterogeneity I2 = 98.7%). (B) After 3 to 4 years follow-
up, average percent reticulocytes decreased following PS by 7.8% (95% CI: -10.7% to -4.9%; 
heterogeneity I2 = 0.0%). (C) After 5 to 6 years follow-up, average hemoglobin concentrations 
increased following PS by 7.7% (95% CI: -10.7 % to 4.7%; heterogeneity I2=0.0%).  
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Table I. Search terms. 
Domain Concept Search terms 
Population 
of interest 
Children (0-
18 yrs) 
“Child”&, “Child, Preschool”&, “Infant”&, “Adolescent”&, 
youth*, juvenile*, teen*, pediatric*, paediatric*, child*, 
preschool*, pre-school, infant* 
Indicator Hereditary 
Spherocytosis 
“Spherocytosis, Hereditary”&, “Anemia”&, “Anemia, 
Hemolytic”&, “Anemia, Hemolytic, Congenital”&, 
“Hemolysis”&, “Hemoglobin”&, “Splenomegaly”&, 
“Splenectomy”&, “Hypersplenism”&, “Jaundice”&, 
spherocyt*, microspherocyt*, splenomega*, splenect*, 
accessor*, hypersplen*, anemi*, anaemi*,hemoly*, haemoly*, 
hemoglobin*, haemoglobin*, jaundice* 
Intervention Splenectomy 
(Total vs 
Partial) 
“Spleen”&, “Splenectomy”&, “Laparotomy”&, 
“Laparoscopy”&, “Hand-Assisted Laparoscopy”&, 
splenectom*, asplen*, ablat*, laparotom*, laparoscop*, total, 
complete, partial, subtotal, sub-total 
Outcome Lab 
parameters, 
adverse 
events, 
morbidity, 
mortality, 
quality of life 
“Treatment Outcome”&, “Hospitalization”&, “Morbidity”&, 
“Mortality”&, “Postoperative Complications”&, 
“Intraoperative Complications”&, followup* OR follow-up*, 
comparison*, morbid*, mortal*, outcome*, complication*, 
adverse* 
Notes: Terms within domains were combined using the OR Boolean operator, while 
combinations of domains were combined using the AND operator.  
& denotes MeSH major headings. All other search terms were text searches. 
* denotes a wildcard. 
 
Table II. Inclusion and exclusion criteria. 
Inclusion Criteria 
Studies report hereditary spherocytosis patients undergoing any form of splenectomy with pre- 
and post-operative hematological parameters or markers of hemolysis, specifically: 
hemoglobin concentrations and peripheral reticulocyte proportion. 
Studies report adverse events, surgical complications or mortality. 
Studies followed a cohort, case-control or case series study design. When case series were 
reported, the chart review was conducted in an unbiased manner, such as an institutional 
review reporting on all cases of hereditary spherocytosis over a specified period of time. 
Data were reported with the value of relative risk (RR), odds ratio (OR) or difference scores 
with 95% confidence intervals (CI); or the raw data needed to calculate these statistics. 
Studies with English title and abstract (for searching), but whose full-text is available in 
English, Italian or French were included. 
Exclusion Criteria 
Single case reports or case series describing <4 patients. or studies that describe a single 
familial experience with HS. 
Letters to the editor or commentaries that did not include full data of the splenectomized 
patients. 
Splenectomies were performed secondary for any other indication than hereditary 
spherocytosis, including blunt trauma, thrombocytopenia purpura, sickle cell anemia, or 
cholelithiasis. 
Data are reported in aggregate of hemolytic anemias, and the spherocytosis-specific data could 
not be obtained either from the article text or by correspondence with the author. 
Studies which exclusively focus on only “mild” cases of spherocytosis, or adult cases, which 
are less likely to require surgical intervention. 
Studies that include adult patients, but for which the individual data or subgroup data are not 
reported by age. 
 
 
 Table III. Characteristics of included studies. 
Study 
(Ref) 
Study 
Design 
Sample 
Size 
Setting & 
Location 
Period 
Splenectomy 
& Procedure 
M:F 
Age at 
Surgery 
Follow-
up 
Risk 
of 
Biasa 
Abdullah 
2009 
[27] 
Retrospective 
cross-section 
1,657 
National 
registry; 
USA 
1988-
2004 
TS, open 830/819 
median: 8.0 y 
range: 5-12 y 
NR Fair 
Bader-
Meunier 
2001 [15] 
Institutional 
case series 
39 
Single 
institution; 
France 
1985-
1998 
PS, open 22/17 8.1 ± 4.3 y (sd) 
12-168 
mo. 
Good 
Buesing 
2011 [16] 
Retrospective 
cohort 
24 
5 pediatric 
centres; 
Canada & 
USA 
1990-
2008 
PS, 
laparoscopy 
12/12 7.4 ± 4.2 (sd) 19 mo. 
Fair 
38 PS, open 19/19 8.2 ± 3.8 y (sd) 48 mo. 
Mariani 
2008 [12] 
Institutional 
case series 
121 
Single 
institution; 
Italy 
1980-
2008 
TS, open NR NR NR Fair 
Mattioli 
2007 [17] 
Selected case 
series 
50 
9 pediatric 
centres; Italy 
Jan 1999 - 
Dec 2003 
TS, 
laparoscopy 
NR 
mean: 10.0 y 
range: 2-10 y 
7-56 mo. Fair 
Morinis 
2008 [18] 
Retrospective 
cohort 
9 Single 
institution; 
Canada 
2000-
2006 
PS, 
laparoscopy 
7/2 9.5 ± 4.2 y (sd) 25 mo. 
Good 
9 
TS, 
laparoscopy 
7/2 8.6 ± 3.8 y (sd) 25 mo. 
Wood 2011 
[26] 
Institutional 
case series 
70 
Pediatric 
centre; USA 
Jan 2000 - 
July 2008 
TS, 
laparoscopy 
(mostly) 
41/29 
mean: 8.9 y 
range: NR 
29-100 d Good 
Rescorla 
2007 [19] 
Prospective 
cohort 
111 
Single 
institution; 
USA 
Aug 1995 
- Nov 
2006 
TS (mostly), 
laparoscopy 
NR 
mean: 7.7 y 
range: 9 mo. - 
19 y 
NR Fair 
Rice 2003 
[20] 
Prospective 
cohort 
16 
Two 
pediatric 
institutions; 
USA 
1993-
2000 
PS, open NR 7.0 ± 3.4 y (sd) 7-72 mo. Fair 
Rice 2015 
[21] 
Retrospective 
cohort 
19 16 
institutions; 
Canada & 
USA 
2005-
2013 
PS, mixed 
19/21 
< 18 yr 
< 18 yr 
NR 
NR 
Fair 
21 TS, mixed 
Seims 2013 
[22] 
Retrospective 
cohort 
87 
Single 
institution; 
USA 
2002-
2012 
PS, 
laparoscopy 
NR 5.5 ± 2.8 y (sd) 24 mo. 
Fair 
TS, 
laparoscopy 
NR 7.1 ± 3.6 y (sd) 13 mo. 
Slater 2010 
[23] 
Selected case 
series 
9 
Single 
institution; 
USA 
May 2005 
- Sept 
2009 
PS, 
laparoscopy 
5/4 
mean: 11.0 y 
range: 5-15 y 
12-42 mo. Fair 
Stoehr 2006 
[24] 
Prospective 
cohort 
31 
Single 
institution; 
Germany 
Nov 1996 
- Dec 
2004 
PS, open 17/14 
mean: 8.7 y 
range: 3-21 y 
9-98 mo. Fair 
Tchernia 
1993 [25] 
Selected case 
series 
11 
Single 
institution; 
France 
NR PS, open NR 7.9 ± 3.1 y (sd) 6-48 mo. Fair 
 adenotes risk of bias assessment using the Downs and Black critical appraisal checklist [13]. Qualitative descriptors 
are: excellent (26–28), good (20–25), fair (15–19) and poor (<=14) [14]. Studies with a “poor” score were excluded 
during the risk of bias assessment. 
TS/PS denotes total or partial splenectomy. NR denotes not reported by author. 
 
  
Supplemental Table S1. MOOSE Checklist for Meta-analyses of Observational Studies 
Item No Recommendation 
Reported on 
Page No 
Reporting of background should include 
1 Problem definition 2-3 
2 Hypothesis statement 3 
3 Description of study outcome(s) 3-4 
4 Type of exposure or intervention used 4 
5 Type of study designs used 3 
6 Study population 3-4 
Reporting of search strategy should include 
7 Qualifications of searchers (eg, librarians and investigators) 3 
8 Search strategy, including time period included in the synthesis and key words 4-5 
9 Effort to include all available studies, including contact with authors 4-5 
10 Databases and registries searched 4 
11 Search software used, name and version, including special features used (eg, explosion) 5 
12 Use of hand searching (eg, reference lists of obtained articles) 4 
13 List of citations located and those excluded, including justification Fig. 1, pp. 5-6 
14 Method of addressing articles published in languages other than English Table 2 
15 Method of handling abstracts and unpublished studies Table 2 
16 Description of any contact with authors 5 
Reporting of methods should include 
17 
Description of relevance or appropriateness of studies assembled for assessing the 
hypothesis to be tested 
Table 2, pp. 5-
6 
18 
Rationale for the selection and coding of data (eg, sound clinical principles or 
convenience) 
4 
19 
Documentation of how data were classified and coded (eg, multiple raters, blinding and 
interrater reliability) 
4 
20 
Assessment of confounding (eg, comparability of cases and controls in studies where 
appropriate) 
5-6 
21 
Assessment of study quality, including blinding of quality assessors, stratification or 
regression on possible predictors of study results 
5-6 
22 Assessment of heterogeneity 
pp. 6-7, Table 
4 
23 
Description of statistical methods (eg, complete description of fixed or random effects 
models, justification of whether the chosen models account for predictors of study 
results, dose-response models, or cumulative meta-analysis) in sufficient detail to be 
replicated 
6 
24 Provision of appropriate tables and graphics Yes 
Reporting of results should include 
25 Graphic summarizing individual study estimates and overall estimate 
Yes, where 
appropriate 
See Fig. 2&4 
and Table 3 
26 Table giving descriptive information for each study included Tables 3 
27 Results of sensitivity testing (eg, subgroup analysis) 
Figures 2 and 
4, and pp. 7-8, 
10 
28 Indication of statistical uncertainty of findings 
Fig 2, Table 4, 
and in 
descriptions of 
results 
  
Reporting of discussion should include 
29 Quantitative assessment of bias (eg, publication bias) 
pp 6-7 and Fig 
3 
30 Justification for exclusion (eg, exclusion of non-English language citations) Table 2 
31 Assessment of quality of included studies Table 3 
Reporting of conclusions should include 
32 Consideration of alternative explanations for observed results Yes 
33 
Generalization of the conclusions (ie, appropriate for the data presented and within the 
domain of the literature review) 
Yes 
34 Guidelines for future research 12-14 
35 Disclosure of funding source No sources 
From: Stroup et al. JAMA. 2000. 
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August 2012. 
